RT Journal Article
SR Electronic
T1 Impact of left ventricular assist devices and heart transplant on acute myocardial infarction and heart failure mortality and readmission measures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19011213
DO 10.1101/19011213
A1 Eric J Brandt
A1 Joseph S. Ross
A1 Jacqueline N. Grady
A1 Tariq Ahmad
A1 Sumeet Pawar
A1 Susannah M. Bernheim
A1 Nihar R Desai
YR 2019
UL http://medrxiv.org/content/early/2019/11/05/19011213.abstract
AB Background Concern has been raised about consequences of including patients with left ventricular assist device (LVAD) or heart transplantation (HT) in readmission and mortality measures.Methods We calculated unadjusted and hospital-specific 30-day risk-standardized mortality (RSMR) and readmission (RSRR) rates for all Medicare fee-for-service beneficiaries with a primary diagnosis of AMI or HF discharged between July 2010 and June 2013. Hospitals were compared before and after excluding LVAD and HT patients. LVAD indication was measured.Results For the AMI and HF cohorts, ≤0.2% of patients received an LVAD and ≤0.1% received HT in either cohort. Less than 2% of hospitals had either ≥6 patients who received an LVAD or, independently, had ≥1 HT. The AMI mortality and readmission cohorts used 1.8% and 2.8% of LVADs for semi-permanent/permanent indications, versus 73.8% and 78.0% for HF patients, respectively. The rest were for temporary/external indications.In the AMI cohort, RSMR for hospitals without LVAD patients versus hospitals with ≥6 LVADs was 14.8% and 14.3%, and RSRR was 17.8% and 18.3%, respectively; the HF cohort RSMR was 11.9% and 9.7% and RSRR was 22.6% and 23.4%, respectively. In the AMI cohort, RSMR for hospitals without versus with HT patients was 14.7% and 13.9% and RSRR was 17.8% and 17.7%, respectively; in the HF cohort, RSMR was 11.9% and 11.0%, and RSRR was 22.6% and 22.6%, respectively. Estimations changed ≤0.1% after excluding LVAD or HT patients.Conclusion Hospitals caring for ≥6 patients with LVAD or ≥1 HT had lower RSMRs but higher RSRRs on average. Rates were insignificantly changed when these patients were excluded. LVADs were primarily for acute-care in the AMI cohort and chronic support in the HF cohort. LVAD and HT patients are a distinct group with differential care requirements and outcomes, thus should be considered separately from the rest of the HF cohort.Competing Interest StatementEric J. Brandt: None Jackie Grady: None Joseph Ross: In the past 36 months, Dr. Ross has received research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. Tariq Ahmad: None Sumeet Pawar: None Nihar Desai: NoneFunding StatementEric J. Brandt: None Jackie Grady: None Joseph Ross: In the past 36 months, Dr. Ross has received research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. Tariq Ahmad: None Sumeet Pawar: None Nihar Desai: NoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are not public data. Data are owned by CMS and not data primarily owned or controlled by any of the authors of this manuscript.